![conference banner](/images/conference-banner.jpeg)
摘要
背景:乳腺癌的患病率正以惊人的速度增长,因此需要探索最相关的诊断生物标志物。 RAD50是编码DNA损伤修复蛋白的癌症易感基因。它在乳腺癌中作为临床病理学特异性生物标志物的作用尚待探索。 目的:本研究旨在探讨具有不同临床病理特征的浸润癌患者中RAD50的表达及其启动子的甲基化水平变化。本研究进一步探讨了RAD50的突变谱及其表达与患者生存率以及治疗药物有效性的相关性。 方法:利用GeneCards平台对RAD50进行富集分析。有关RAD50表达,其启动子甲基化以及对患者生存的影响的信息可从TCGA和CPTAC数据库中检索到。但是,通过CCLE和GDSC数据集的基因组分析,得出了RAD50表达对肿瘤对多种药物反应的影响。 结果:在乳腺癌浸润癌的各个亚组中均发现了启动子高甲基化和RAD50表达升高。除绝经后的受试者外,观察到具有低/中等表达水平的受试者比显示高RAD50的患者存活更长的时间。 RAD50中错义突变的频率高于截短突变。发现大多数药物与RAD50表达呈正相关。 结论:RAD50启动子的甲基化状态与RAD50的表达水平呈负相关。 RAD50在乳腺癌患者中过表达,因此使肿瘤对许多抗癌药物具有耐药性。
关键词: RAD50,乳腺癌,CCLE药物,生存分析,突变图,MRN复合体,表达。
Current Cancer Drug Targets
Title:Overexpression of RAD50 is the Marker of Poor Prognosis and Drug Resistance in Breast Cancer Patients
Volume: 21 Issue: 2
关键词: RAD50,乳腺癌,CCLE药物,生存分析,突变图,MRN复合体,表达。
摘要:
Background: The prevalence of breast cancer is increasing at an alarming rate and thus demands exploration of the most relevant diagnostic biomarkers. RAD50 is a cancer susceptibility gene that encodes a DNA damage repairing protein. Its role in breast cancer as clinico-pathological specific biomarker has yet to be explored.
Objective: This study was aimed to investigate the RAD50 expression and its promoter’s methylation level variations in breast invasive carcinoma patients having different clinico-pathological features. This study further explored the mutational spectrum of RAD50 and the correlation of its expression with the survival of patients and the effectiveness of drugs used for treatment.
Methods: Enrichment analysis of RAD50 was accomplished using the platform of GeneCards. The information regarding RAD50 expression, its promoter methylation and impact on survival of patient was retrieved from TCGA and CPTAC databases. However, the effect of RAD50 expression on tumor’s response to various drugs was deduced through the analysis of CCLE and genomic of GDSC dataset.
Results: The promoter hyper-methylation and elevated expression of RAD50 was documented in various subgroups of breast invasive carcinoma. The subjects having low/medium expression levels were observed to survive longer than patients exhibiting high expression of RAD50 except for post-menopausal subjects. The frequency of missense mutations was higher in RAD50 than truncating mutations. Most of the drugs were found to have a positive correlation with RAD50 expression.
Conclusion: The status of RAD50 promoter’s methylation inversely correlates with the expression level of RAD50. While RAD50 is overexpressed in breast cancer patients and thus makes tumor resistant against many anti-cancer drugs.
Export Options
About this article
Cite this article as:
Overexpression of RAD50 is the Marker of Poor Prognosis and Drug Resistance in Breast Cancer Patients, Current Cancer Drug Targets 2021; 21 (2) . https://dx.doi.org/10.2174/1568009620666201009125507
DOI https://dx.doi.org/10.2174/1568009620666201009125507 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process of exploring and investigating the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Hybrid Molecules Based on triazole-β-lactam as Potential Biological Agents
Mini-Reviews in Medicinal Chemistry Association of Metronidazole with Cancer: A Potential Risk Factor or Inconsistent Deductions?
Current Drug Metabolism Tumor Organoid Model and Its Pharmacological Applications in Tumorigenesis Prevention
Current Molecular Pharmacology Bradykinin Antagonists as Anti-Cancer Agents
Current Pharmaceutical Design Computational Study of the Binding Modes of Diverse DPN Analogues on Estrogen Receptors (ER) and the Biological Evaluation of a New Potential Antiestrogenic Ligand
Anti-Cancer Agents in Medicinal Chemistry Stimuli Responsive Nanoparticles for Controlled Anti-cancer Drug Release
Current Medicinal Chemistry Implications of Melatonin Therapy in Irritable Bowel Syndrome: A Systematic Review
Current Pharmaceutical Design Comprehensive Analysis of Key Proteins Involved in Radioresistance of Prostate Cancer by Integrating Protein-protein Interaction Networks
Current Bioinformatics Adjuvant Approach to Mitigate the Adverse Effects of Cancer Treatments Using Homeopathic Medicines
Current Cancer Therapy Reviews Simulated Microgravity Based Stem Cell Cultures Enhance Their Utility for Cell-Based Therapy
Current Biotechnology The Metastatic Process: Methodological Advances and Pharmacological Challenges
Current Medicinal Chemistry Intratumoral and Peritumoral Edema Radiomics Based on Fat-Suppressed T2- Weighted Imaging for Preoperative Prediction of Triple-Negative Breast Cancer
Current Medical Imaging Using Protein-protein Interaction Network Information to Predict the Subcellular Locations of Proteins in Budding Yeast
Protein & Peptide Letters Yoga can Alter the Autonomic Neural Activity: A Critical Analysis
Current Traditional Medicine Phase II Drug Metabolism and Individualized Drug Therapy: A Focus on Functional Genetic Variation in UDP-Glucuronosyltransferases
Current Pharmacogenomics and Personalized Medicine Advances in Drug Safety
Current Pharmaceutical Design Multitargeted Molecular Docking Study of Natural-Derived Alkaloids on Breast Cancer Pathway Components
Current Computer-Aided Drug Design Overview: Translating Hsp90 Biology into Hsp90 Drugs
Current Cancer Drug Targets Recent Clinical Trials of mTOR-Targeted Cancer Therapies
Reviews on Recent Clinical Trials From Nucleic Acids to Drug Discovery: Nucleobases as Emerging Templates for Drug Candidates
Current Medicinal Chemistry